Equities

Alvotech SA

Alvotech SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.07
  • Today's Change0.06 / 0.54%
  • Shares traded96.67k
  • 1 Year change+21.78%
  • Beta-0.0724
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

  • Revenue in USD (TTM)308.73m
  • Net income in USD-618.38m
  • Incorporated2021
  • Employees999.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Geron Corp1.37m-219.55m2.74bn141.00--8.92--1,997.61-0.3595-0.35950.00230.51030.0032--0.63679,737.59-50.78-51.32-63.77-64.9063.00---15,990.60-19,949.133.60--0.2139---60.23-25.97-29.76--120.29--
Apogee Therapeutics Inc0.00-118.49m2.96bn91.00--3.71-----2.25-2.250.0013.650.00----0.00-25.44---26.65--------------0.00-------111.10------
Ideaya Biosciences Inc11.96m-153.74m3.02bn124.00--2.92--252.74-2.18-2.180.171812.240.0159--148.5796,451.61-20.48-19.17-21.42-21.05-----1,285.44-244.55----0.00---54.08---92.59--6.75--
Xenon Pharmaceuticals Inc0.00-199.06m3.04bn251.00--3.59-----2.74-2.740.0011.150.00----0.00-25.38-20.71-26.37-21.81-------683.58----0.00---100.00---45.99--61.77--
Kymera Therapeutics Inc88.55m-157.85m3.05bn181.00--4.25--34.40-2.41-2.411.3611.120.1258--30.40473,529.40-22.42-23.03-24.45-27.64-----178.27-207.82----0.0028--67.84--5.07--91.01--
Guardant Health Inc643.81m-490.76m3.09bn1.78k------4.79-4.09-4.095.36-0.01310.37334.046.89361,894.30-28.46-22.26-32.21-24.5959.9564.62-76.23-97.076.07-10.181.00--25.4544.1426.76--0.2786--
Iovance Biotherapeutics Inc32.77m-440.22m3.16bn557.00--4.03--96.50-1.68-1.680.12452.590.03812.402.0758,836.63-51.14-51.47-57.20-57.56-37.43---1,343.27-137,873.804.85--0.0013-------12.16--79.44--
Rhythm Pharmaceuticals Inc101.78m-260.73m3.25bn226.00--82.57--31.94-4.37-4.371.712.940.29431.256.48450,367.30-75.00-47.21-87.80-52.8488.80---254.88-681.386.31--0.3765--227.56---1.97---42.10--
MoonLake Immunotherapeutics0.00-54.80m3.26bn50.00--6.16-----0.9043-0.90430.008.280.00----0.00-11.08---11.49--------------0.00------27.95------
Alvotech SA308.73m-618.38m3.32bn999.00------10.75-2.65-2.651.28-2.270.3121.803.66309,038.00-62.49---222.85--48.79---200.30--0.1569-0.23232.04--9.84---7.43------
Amicus Therapeutics, Inc.455.66m-119.54m3.32bn517.00--25.05--7.29-0.397-0.3971.510.44710.61590.69486.12881,344.30-16.16-30.65-20.75-36.5589.8888.94-26.23-86.102.26-0.61340.7459--21.3034.3535.92--3.36--
Dyne Therapeutics Inc0.00-257.60m3.47bn152.00--4.47-----3.58-3.580.007.740.00----0.00-47.82-52.81-50.15-57.45------------0.00-------40.36--40.32--
Biohaven Ltd0.00-746.61m3.69bn239.00--9.39-----9.15-9.150.004.160.00----0.00-137.07---176.64--------------0.00------28.43------
TG Therapeutics Inc346.73m95.69m3.88bn300.0041.7921.8740.5111.200.60010.60012.291.151.110.45056.861,313,356.0030.76-62.8743.42-80.0692.76--27.60-405.032.838.210.3661--8,290.02333.86106.39------
Data as of Sep 18 2024. Currency figures normalised to Alvotech SA's reporting currency: US Dollar USD

Institutional shareholders

4.44%Per cent of shares held by top holders
HolderShares% Held
Bracebridge Capital LLCas of 30 Jun 20242.71m0.90%
Oaktree Capital Management LPas of 30 Jun 20242.53m0.84%
The Vanguard Group, Inc.as of 30 Jun 20242.44m0.81%
Littlejohn & Co. LLC (Investment Management)as of 30 Jun 20241.32m0.44%
Sculptor Capital LPas of 30 Jun 2024945.10k0.31%
Balyasny Asset Management LPas of 30 Jun 2024848.44k0.28%
PointState Capital LPas of 30 Jun 2024730.07k0.24%
Lodbrok Capital LLPas of 30 Jun 2024715.81k0.24%
Vanguard Fiduciary Trust Co.as of 30 Jun 2024638.08k0.21%
Legal & General Investment Management Ltd.as of 30 Jun 2024543.87k0.18%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.